Phenylboronic acid conjugation to a cationic antimicrobial peptide created a tumor-selective agent (PBA-AMP) that achieved 3× better cancer cell killing (IC50 38.5 vs 110 μM) and suppressed tumor growth in vivo.
3× improved killingSimple boronic acid modification tripled the peptide's cancer cell killing ability while adding tumor selectivity
What the researchers found
PBA-AMP showed tumor-selective binding via sialic acid targeting, 3× improved MCF-7 cytotoxicity (IC50 38.46 vs 110 μM), selective tumor accumulation in vivo, and significant tumor suppression in 4T1 mice without systemic toxicity.
Why it matters
Making antimicrobial peptides tumor-selective through simple chemical modification opens a new approach to targeted cancer therapy that is simpler and potentially cheaper than antibody-based targeting.
How the study worked
Chemical conjugation of PBA to cationic AMP, MD simulations (50 ns), MCF-7 cellular uptake/cytotoxicity assays, in vivo imaging for tumor accumulation, and 4T1 tumor-bearing mouse efficacy study.
What this study cannot tell us
Mouse model with single tumor type (4T1). IC50 of 38.5 μM is relatively high for clinical drugs. PBA may also bind sialic acid on some normal cells. Pharmacokinetics not fully characterized.
How to read the evidence
Preclinical study with computational, in vitro, and in vivo validation. Well-designed rational approach with clear proof of concept.
When this study was published
Published in 2025.
The bigger picture
This rational design strategy—exploiting tumor surface sugar differences for peptide targeting—could be applied to many therapeutic peptides beyond antimicrobial ones.
Questions still open
- Can PBA-AMP potency be further improved through sequence optimization?
- Would PBA modification work with other therapeutic peptides?
- How does PBA-AMP compare to antibody-drug conjugates for tumor targeting?
Common questions
How does this peptide find tumors?
Could this become a cancer treatment?
Read the original research
Rational Design of a Bioconjugated Antitumor Peptide with Tumor-Selective Targeting and Microenvironment-Responsive Activation.
Pharmaceutical research, 43(1), 123-136
Citation
Feng, Chunlai; Deng, Wen; Cai, Min; Hu, Yujiao; Liang, Wenyan; Dong, Hangyu; Rui, Mengjie. (2026). Rational Design of a Bioconjugated Antitumor Peptide with Tumor-Selective Targeting and Microenvironment-Responsive Activation.. Pharmaceutical research, 43(1), 123-136. https://doi.org/10.1007/s11095-025-03990-5